Investment Rating - The report assigns a rating of "Buy" to the company with a target price of 48.38 CNY, compared to the current price of 30.15 CNY [5]. Core Insights - The company is expected to achieve steady revenue growth in 2026, with a projected revenue of 12.61 billion CNY, driven by the successful renewal of medical insurance for its core products, Xidabena and Siglitazone, which are anticipated to see significant volume growth [11][15]. - Xidabena is expected to reach clinical endpoints for multiple core indications in 2026, including global Phase III trials for 1L MEL and Chinese Phase III trials for 3L+ CRC [18][22]. - The company is also advancing the development of several new drugs, with multiple early-stage candidates expected to report data in 2026, marking a significant period for research and development [33][34]. Financial Summary - The financial outlook shows total revenue increasing from 524 million CNY in 2023 to 1,261 million CNY in 2026, representing a compound annual growth rate (CAGR) of approximately 38.6% [4]. - Net profit is projected to improve significantly, with a forecast of 166 million CNY in 2026, following a loss of 115 million CNY in 2024 [4]. - The earnings per share (EPS) is expected to rise from -0.26 CNY in 2024 to 0.38 CNY in 2026, indicating a turnaround in profitability [4]. Product Development and Clinical Trials - The company is focusing on expanding the indications for Xidabena, with ongoing clinical trials expected to yield results in 2026, which could provide a substantial growth catalyst [18][21]. - The efficacy of Xioroni in treating pancreatic cancer has shown promising results, with ongoing trials expected to report data in 2026, enhancing its competitive position in the global market [28][29]. - Several new drug candidates, including TYK2 inhibitors and PDL1 oral small molecules, are anticipated to complete initial clinical phases and disclose data in 2026, indicating a robust pipeline [33][34].

Investment Rating - The report assigns a rating of "Buy" to the company with a target price of 48.38 CNY, compared to the current price of 30.15 CNY [5][11]. Core Insights - The company is expected to achieve steady revenue growth in 2026, with a projected revenue of 12.61 billion CNY, driven by the successful renewal of medical insurance for its core products, Xidabena and Xiglitazone, which are anticipated to see significant volume growth [11][15][16]. - The report highlights that multiple core indications for Xidabena are expected to reach clinical endpoints in 2026, providing a continuous growth impetus for the company [18][22]. - The efficacy of Xioroni in treating pancreatic cancer is noted to be outstanding, positioning it competitively on a global scale [28][29]. - Several new drugs are expected to report data in 2026, marking a significant period for the company's research and development achievements [33]. Financial Summary - The company’s total revenue is projected to grow from 910 million CNY in 2025 to 1,261 million CNY in 2026, reflecting a year-on-year increase of 38.6% [4]. - Net profit attributable to the parent company is expected to rise from 51 million CNY in 2025 to 166 million CNY in 2026, indicating a substantial recovery from a loss of 115 million CNY in 2024 [4]. - The earnings per share (EPS) is forecasted to increase from 0.12 CNY in 2025 to 0.38 CNY in 2026, further demonstrating the company's improving profitability [4]. Product Development and Clinical Trials - Xidabena is undergoing multiple pivotal clinical trials, with significant studies expected to report results in 2026, including trials for 1L MEL and 3L+ CRC [19][21]. - Xioroni is also advancing in clinical trials for first-line pancreatic cancer, with promising early results that suggest a competitive edge in the market [28][30]. - The company is actively developing several new drugs, including TYK2 inhibitors and PDL1 oral small molecules, which are anticipated to complete initial clinical phases in 2026 [33][35].

Core Insights - The company is expected to achieve profitability by 2025, with significant breakthroughs in international expansion and promising clinical data for its product, Westoroni, in the pancreatic cancer field [1][2]. Financial Performance - The company's revenue forecast for 2025 is projected at 910 million yuan, representing a year-on-year growth of 38.32% [2]. - The net profit attributable to shareholders is expected to be 53.46 million yuan, marking a turnaround from previous losses [2]. - Key products, including Sigleth sodium, have seen a sales revenue increase of approximately 123% year-on-year, while Sidabamine, despite facing price reductions from insurance, still achieved a 16% growth [2]. Recent Developments - On February 10, 2026, the company announced progress in its international expansion, granting exclusive rights for Sidabamine to Russian pharmaceutical company Nizhpharm in the CIS and Central Asia, which includes an upfront payment of 10 million yuan [3]. - The updated Phase II clinical data for Westoroni in combination chemotherapy shows a 50% objective response rate (ORR) and a median progression-free survival (mPFS) of 9.1 months, supporting further development [3]. Stock Performance - Over the past week (February 5 to 11, 2026), the company's stock price fluctuated between a high of 32.47 yuan and a low of 30.75 yuan, with a total decline of 0.76% [4]. - On February 10, the stock price increased by 1.28%, with a net inflow of 28.19 million yuan from major funds; however, it closed at 31.21 yuan on February 11, down 1.73% for the day [4]. - The financing balance has been increasing, with a recent growth of 5.57% over the past five days [4].

Group 1: Company Performance - Microchip Biotech forecasts a turnaround to profitability in 2025, with projected revenue of 910 million yuan, a year-on-year increase of 38.32% [1] - The net profit attributable to shareholders is expected to reach 53.46 million yuan, a significant improvement from a loss of 115 million yuan in the previous year, marking an increase of 168 million yuan [1] - Revenue growth is primarily driven by the commercialization of core products, with sales of Sigleptin sodium increasing approximately 123% due to its clinical value in "diabetes-liver management" and effective collaboration between self-operated and channel sales [1] - Sales of Sidabamine, despite facing price reductions and inventory adjustments, still achieved a year-on-year growth of 16% after being included in the national medical insurance catalog for a new indication of diffuse large B-cell lymphoma [1] Group 2: Strategic Developments - The company has made a breakthrough in business development by granting exclusive rights for Sidabamine to the Russian pharmaceutical company Nizhpharm for research, registration, and commercialization in 12 CIS and Central Asian countries [2] - Nizhpharm will pay an upfront fee of 10 million yuan and a milestone payment of 10 million yuan upon registration, along with a high double-digit percentage of net sales in the authorized regions [2] - Sidabamine is the world's first subtype-selective HDAC inhibitor, approved for multiple indications in China and Japan, and is currently undergoing Phase III clinical trials for additional indications [2] Group 3: Clinical Research Updates - Xioroni has updated data on pancreatic cancer, showing potential in treatment through both single-agent exploration in the U.S. and combination chemotherapy in China [3] - In a Phase II study for first-line treatment of pancreatic ductal adenocarcinoma, Xioroni combined with AG chemotherapy demonstrated a breakthrough efficacy potential, achieving an objective response rate (ORR) of 50% [3] - The median progression-free survival (mPFS) is reported at 9.1 months, with approximately half of the patients still on treatment after a median follow-up of 9.6 months [3] - Xioroni shows promising synergy with targeted drugs like RAS inhibitors in various mouse models, indicating enhanced tumor suppression effects when combined [3] - The U.S. Phase I dose-escalation trial for Xioroni is nearing completion, with the company actively advancing its overseas development and collaboration efforts [3]

Summary of Key Points from the Conference Call Company Overview - The report focuses on Microchip Biotech, a company in the pharmaceutical industry, specifically analyzing its performance in 2025 and projections for 2026 [1] Financial Performance - In 2025, the company achieved a revenue of 910 million yuan, representing a year-over-year increase of 38% [1] - The revenue from the drug Sidabamine grew by 16% and it was included in the regular medical insurance directory [1] - The revenue from the drug Siglethana increased by 123%, indicating rapid growth for both products [1] - The net profit attributable to the parent company for 2025 was 53 million yuan, with a non-recurring profit of 38 million yuan, significantly improving from a net loss of 115 million yuan and a non-recurring loss of 205 million yuan in 2024 [1] - In Q4 2025, the company reported revenue of approximately 236 million yuan, a year-over-year increase of 33%, although there was a slight quarter-over-quarter decline due to price adjustments following the inclusion of Sidabamine in medical insurance [1] - The net profit attributable to the parent company in Q4 2025 was approximately -18 million yuan, with a non-recurring net profit of about -20 million yuan, both showing significant reduction in losses compared to previous periods [1] Future Projections - For 2026, the company anticipates continued data readouts, with key clinical results expected for several drugs [2] - The clinical results for Sidabamine in CRC Phase III are expected to be available by the end of 2026 to early 2027 [2] - The clinical results for Seoroni in PDAC Phase II are expected to mature by mid-2026 [2] - Additionally, preliminary human exploration results for oral PDL1 small molecules, TYK2 inhibitors, and next-generation AURORAB inhibitors are anticipated in the second half of 2026 [2] Additional Insights - The inclusion of Sidabamine in the medical insurance directory is a significant milestone that may enhance its market penetration and revenue potential [1] - The rapid growth rates of both Sidabamine and Siglethana suggest a strong demand and effective market strategies [1] - The company’s ability to reduce losses significantly indicates improving operational efficiency and potential for future profitability [1][2]

Core Viewpoint - The major shareholder of Microchip Biotech, Boao Biological Group, has completed a share reduction plan, selling 12.23 million shares, which is 3% of the company's total equity, for approximately 322 million yuan. This reduction will not significantly impact the company's governance structure or operations [2][7][8]. Group 1: Shareholder Actions - Boao Biological Group, the largest shareholder of Microchip Biotech, held 34.71 million shares (8.51% of total equity) before the reduction [7]. - The share reduction was initiated on September 11, 2025, due to strategic funding needs, with a plan to sell up to 12.23 million shares through a combination of centralized bidding and block trading [7][8]. - The reduction was executed between October 14 and November 26, 2025, with a total of 407.80 million shares sold through centralized bidding and 815.59 million shares through block trading, at prices ranging from 23.59 yuan to 31.10 yuan per share [8]. Group 2: Company Financing Plans - Microchip Biotech is advancing a plan to issue A-shares to specific investors, aiming to raise up to 950 million yuan for innovative drug research, the construction of a new drug manufacturing base, and to supplement working capital [9]. - The fundraising plan has been approved by the company's board and shareholders, pending approval from the Shanghai Stock Exchange and registration with the China Securities Regulatory Commission [9]. - The funds will be allocated as follows: 350 million yuan for innovative drug research, 350 million yuan for the first phase of the new drug manufacturing base, and 250 million yuan for working capital [11]. Group 3: Research and Development Focus - Microchip Biotech is focusing on multiple key Phase II and III clinical trials, including a Phase II study for a combination treatment for advanced pancreatic ductal adenocarcinoma and a Phase III study for a colorectal cancer indication [11][12]. - The company reported significant revenue growth for its products, with a 125.7% year-on-year increase for one drug in the first half of 2025 and an 18.8% increase for another in the same period [11][12].

Core Viewpoint - The major shareholder of Microchip Biotech, Boao Biological Group, has completed a share reduction plan, selling 12.23 million shares, which is 3% of the company's total shares, for approximately 322 million yuan. This reduction will not significantly impact the company's governance structure or operations [1][5][6]. Group 1: Shareholder Actions - Boao Biological Group, the largest shareholder of Microchip Biotech, has reduced its holdings from 8.51% to 5.51% after selling 12.23 million shares [6]. - The share reduction was executed between October 14 and November 26, 2025, with a total sale amount of 322 million yuan, and the share price ranged from 23.59 yuan to 31.10 yuan [6][5]. - The market reaction to the share reduction was minimal, with only a 0.32% decline in the stock price during the reduction period [6]. Group 2: Fundraising and Investment Plans - Microchip Biotech is advancing a plan to issue A-shares to specific investors, aiming to raise up to 950 million yuan for innovative drug research, the construction of a new drug manufacturing base, and to supplement working capital [7][8]. - The fundraising plan has been approved by the company's board and shareholders, pending regulatory approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [7]. - The allocation of the raised funds includes 350 million yuan for innovative drug research, 350 million yuan for the first phase of the new drug manufacturing base, and 250 million yuan for working capital [7][8]. Group 3: Drug Development Progress - Microchip Biotech is focusing on multiple key Phase II and III clinical trials, including a Phase II study for a combination treatment for advanced pancreatic cancer and a Phase III trial for a colorectal cancer treatment [8][9]. - The company reported significant revenue growth for its drugs, with a 125.7% increase for one drug in the first half of 2025 and an 18.8% increase for another in the same period [8][9].

Core Viewpoint - Microchip Biotech (688321) has experienced a slight decline in stock price, closing at 30.41 yuan, down 1.49% from the previous week, with a current market capitalization of 12.401 billion yuan [1] Group 1: Clinical Research Updates - The Phase II clinical trial of Xioroni for pancreatic cancer has enrolled 42 patients, with a 6-month progression-free survival (PFS) rate of nearly 80%, showing better efficacy compared to historical chemotherapy results [3][9] - The sales of Sigleth sodium increased by 125.7% in the first half of 2025, with a year-on-year growth rate of 136.1% in the first three quarters, attributed to successful self-operated and commissioned sales models [4][9] - The Phase III clinical trial of Sidabamine for colorectal cancer has enrolled over 300 patients, leading the domestic competition in similar indications, with expectations to complete most patient enrollments by 2025 [7][9] Group 2: Company Announcements - Microchip Biotech plans to repurchase shares amounting to no less than 10 million yuan and no more than 15 million yuan, with a repurchase price not exceeding 47.46 yuan per share, within a 12-month period [10] - The company has completed GMP compliance checks for the third production line of Sigleth sodium and is advancing GMP certification for the new formulation line, with plans to add a production capacity of 1.2 billion tablets by 2027 [6][9] - The top ten shareholders include Boao Biological Group, holding 30,627,198 shares, representing 7.51% of the total shares [8]

Core Insights - The company reported a significant increase in revenue and net profit for the first three quarters of 2025, driven by the strong performance of its core products, Sidabenan and Siglecatin [1] - The company’s third-quarter results showed a remarkable year-on-year growth in both revenue and net profit, attributed to successful sales strategies and the inclusion of Sidabenan in medical insurance [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 674 million yuan, a year-on-year increase of 40.12%, with Sidabenan sales up 18.76% and Siglecatin sales up 136.13% [1] - The net profit attributable to the parent company for the same period was 71 million yuan, reflecting a year-on-year growth of 238.53%, while the net profit excluding non-recurring items was 58 million yuan, up 201.17% [1] - In Q3 2025, the company reported a revenue of 268 million yuan, a 49.51% increase year-on-year, and a net profit of 41 million yuan, which is a staggering 508.54% increase year-on-year [1] Clinical Developments - The Sidabenan combination therapy was included in the CSCO treatment guidelines with a top-level I recommendation, indicating strong clinical support [2] - The DEB study results showed a 54-month event-free survival rate of 52.5% for the treatment group, significantly better than the control group, enhancing the efficacy of first-line treatment for double-expressing DLBCL [2] - Ongoing clinical trials for Sidabenan in various cancer treatments are progressing well, with significant patient enrollment expected to be completed by 2025 [3] Future Projections - The company forecasts revenues of 935 million yuan, 1.42 billion yuan, and 2.03 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 42.14%, 51.78%, and 43.23% [4] - Projected net profits for the same years are 102 million yuan, 126 million yuan, and 180 million yuan, with growth rates of 188.63%, 23.78%, and 43.60% [4]

Group 1 - Microchip Biotech (688321) conducted a roadshow on November 3, 2025, with participation from various securities and investment firms [1] - The company is advancing a Phase II clinical study of Xioroni in China for the first-line treatment of advanced pancreatic ductal adenocarcinoma, with a target enrollment of 42 patients and a 6-month progression-free survival (PFS) rate of nearly 80% [2] - The company reported significant growth in its two main products, with Xigletin sodium achieving a 136.1% year-on-year increase in the first three quarters of 2025, driven by a successful "self-operated + agency" model [3] Group 2 - Xidabening's performance in the first three quarters of 2025 also showed an 18.8% year-on-year growth, benefiting from its inclusion in the national medical insurance and positive clinical trial results [3] - The company is expanding its production capacity for Xigletin sodium, with plans to add 1.2 billion tablets by 2027 to meet growing market demand [6] - Xidabening is currently in Phase III clinical trials for colorectal cancer, with promising results showing a 64.0% PFS rate in a recent study [7][8] Group 3 - The company's financial performance for the first three quarters of 2025 includes a main revenue of 674 million yuan, a year-on-year increase of 40.12%, and a net profit of 70.77 million yuan, up 238.53% [8] - The gross profit margin stands at 87.29%, indicating strong profitability [8] - Recent institutional ratings for the stock include three buy ratings and one hold rating [8]